S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
China's 1st domestically made passenger plane completes maiden commercial flight
Bank Collapse Causes Gold Prices to Soar (Ad)
In Nigeria’s hard-hit north, families seek justice as armed groups seek control
Biden and McCarthy reach a final deal to avoid US default and now must sell it to Congress
Bank Collapse Causes Gold Prices to Soar (Ad)
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
Sell every Stock except ONE (Ad)
'Succession' fans brace for series finale of Emmy-winning hit drama
Turkey's Erdogan wins another term as president, extends rule into 3rd decade
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
China's 1st domestically made passenger plane completes maiden commercial flight
Bank Collapse Causes Gold Prices to Soar (Ad)
In Nigeria’s hard-hit north, families seek justice as armed groups seek control
Biden and McCarthy reach a final deal to avoid US default and now must sell it to Congress
Bank Collapse Causes Gold Prices to Soar (Ad)
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
Sell every Stock except ONE (Ad)
'Succession' fans brace for series finale of Emmy-winning hit drama
Turkey's Erdogan wins another term as president, extends rule into 3rd decade
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
China's 1st domestically made passenger plane completes maiden commercial flight
Bank Collapse Causes Gold Prices to Soar (Ad)
In Nigeria’s hard-hit north, families seek justice as armed groups seek control
Biden and McCarthy reach a final deal to avoid US default and now must sell it to Congress
Bank Collapse Causes Gold Prices to Soar (Ad)
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
Sell every Stock except ONE (Ad)
'Succession' fans brace for series finale of Emmy-winning hit drama
Turkey's Erdogan wins another term as president, extends rule into 3rd decade
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
China's 1st domestically made passenger plane completes maiden commercial flight
Bank Collapse Causes Gold Prices to Soar (Ad)
In Nigeria’s hard-hit north, families seek justice as armed groups seek control
Biden and McCarthy reach a final deal to avoid US default and now must sell it to Congress
Bank Collapse Causes Gold Prices to Soar (Ad)
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
Sell every Stock except ONE (Ad)
'Succession' fans brace for series finale of Emmy-winning hit drama
Turkey's Erdogan wins another term as president, extends rule into 3rd decade
NASDAQ:JAZZ

Jazz Pharmaceuticals (JAZZ) Stock Forecast, Price & News

$125.90
-1.65 (-1.29%)
(As of 05/26/2023 ET)
Compare
Today's Range
$125.78
$127.79
50-Day Range
$125.90
$147.16
52-Week Range
$125.35
$163.31
Volume
623,400 shs
Average Volume
500,486 shs
Market Capitalization
$8.06 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$200.75

Jazz Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.88 Rating Score
Upside/​Downside
59.5% Upside
$200.75 Price Target
Short Interest
Bearish
4.64% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.96
Upright™ Environmental Score
News Sentiment
1.02mentions of Jazz Pharmaceuticals in the last 14 days
Based on 12 Articles This Week
Insider Trading
Selling Shares
$2.13 M Sold Last Quarter
Proj. Earnings Growth
13.74%
From $14.70 to $16.72 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.77 out of 5 stars

Medical Sector

61st out of 1,012 stocks

Pharmaceutical Preparations Industry

24th out of 495 stocks


JAZZ stock logo

About Jazz Pharmaceuticals (NASDAQ:JAZZ) Stock

Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development, and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain, and psychiatry. Its product portfolio includes: Xyrem, Xywav, Epidolex, Zepzelca, Rylaze, Vyxeos, and Defitelio. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.

Receive JAZZ Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Jazz Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

JAZZ Stock News Headlines

BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
10-Q: WEREWOLF THERAPEUTICS, INC.
See More Headlines
Receive JAZZ Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Jazz Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

JAZZ Company Calendar

Last Earnings
3/01/2023
Today
5/28/2023
Next Earnings (Estimated)
8/02/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Sector
Medical
Current Symbol
NASDAQ:JAZZ
CUSIP
G5087110
Employees
2,800
Year Founded
2003

Price Target and Rating

Average Stock Price Forecast
$200.75
High Stock Price Forecast
$212.00
Low Stock Price Forecast
$187.00
Forecasted Upside/Downside
+59.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.88
Research Coverage
8 Analysts

Profitability

Net Income
$-224,060,000.00
Pretax Margin
-8.67%

Debt

Sales & Book Value

Annual Sales
$3.66 billion
Cash Flow
$22.09 per share
Book Value
$52.11 per share

Miscellaneous

Free Float
61,184,000
Market Cap
$8.06 billion
Optionable
Optionable
Beta
0.75

Social Links


Key Executives

  • Bruce C. CozaddBruce C. Cozadd
    Chairman & Chief Executive Officer
  • Daniel N. Swisher
    President
  • Renée D. Galá
    Chief Financial Officer & Executive Vice President
  • Robert Iannone
    Executive Vice President-Research & Development
  • Finbar LarkinFinbar Larkin
    Senior Vice President-Technical Operations













JAZZ Stock - Frequently Asked Questions

Should I buy or sell Jazz Pharmaceuticals stock right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Jazz Pharmaceuticals in the last year. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" JAZZ shares.
View JAZZ analyst ratings
or view top-rated stocks.

What is Jazz Pharmaceuticals' stock price forecast for 2023?

8 brokers have issued 12 month price objectives for Jazz Pharmaceuticals' shares. Their JAZZ share price forecasts range from $187.00 to $212.00. On average, they expect the company's share price to reach $200.75 in the next twelve months. This suggests a possible upside of 59.5% from the stock's current price.
View analysts price targets for JAZZ
or view top-rated stocks among Wall Street analysts.

How have JAZZ shares performed in 2023?

Jazz Pharmaceuticals' stock was trading at $159.31 at the beginning of 2023. Since then, JAZZ stock has decreased by 21.0% and is now trading at $125.90.
View the best growth stocks for 2023 here
.

When is Jazz Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 2nd 2023.
View our JAZZ earnings forecast
.

How were Jazz Pharmaceuticals' earnings last quarter?

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) issued its quarterly earnings data on Wednesday, March, 1st. The specialty pharmaceutical company reported ($0.84) earnings per share (EPS) for the quarter. The specialty pharmaceutical company earned $972.12 million during the quarter, compared to the consensus estimate of $972.70 million. Jazz Pharmaceuticals had a positive trailing twelve-month return on equity of 24.72% and a negative net margin of 4.18%.

What guidance has Jazz Pharmaceuticals issued on next quarter's earnings?

Jazz Pharmaceuticals issued an update on its FY 2023 earnings guidance on Friday, May, 12th. The company provided EPS guidance of $16.90-$17.85 for the period, compared to the consensus estimate of $17.44. The company issued revenue guidance of $3.67 billion-$3.88 billion, compared to the consensus revenue estimate of $3.78 billion.

What is Bruce C. Cozadd's approval rating as Jazz Pharmaceuticals' CEO?

60 employees have rated Jazz Pharmaceuticals Chief Executive Officer Bruce C. Cozadd on Glassdoor.com. Bruce C. Cozadd has an approval rating of 92% among the company's employees. This puts Bruce C. Cozadd in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Jazz Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Jazz Pharmaceuticals investors own include Ligand Pharmaceuticals (LGND), Gilead Sciences (GILD), Alibaba Group (BABA), Micron Technology (MU), NVIDIA (NVDA), Netflix (NFLX), Tesla (TSLA), AbbVie (ABBV), Bank of America (BAC) and Biogen (biib).

What is Jazz Pharmaceuticals' stock symbol?

Jazz Pharmaceuticals trades on the NASDAQ under the ticker symbol "JAZZ."

Who are Jazz Pharmaceuticals' major shareholders?

Jazz Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (10.40%), State Street Corp (3.64%), LSV Asset Management (3.66%), JPMorgan Chase & Co. (3.32%), Wellington Management Group LLP (2.90%) and Polaris Capital Management LLC (2.07%). Insiders that own company stock include Anne Oriordan, Bruce C Cozadd, Bruce C Cozadd, Christopher J Tovey, Elmar Schnee, Finbar Larkin, James E Flynn, Jennifer E Cook, Kenneth W O'keefe, Kim Sablich, Mark Douglas Smith, Neena M Patil, Patricia Carr, Patrick G Enright, Paul L Berns, Peter Gray, Renee D Gala, Robert Iannone and Samantha Pearce.
View institutional ownership trends
.

How do I buy shares of Jazz Pharmaceuticals?

Shares of JAZZ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Jazz Pharmaceuticals' stock price today?

One share of JAZZ stock can currently be purchased for approximately $125.90.

How much money does Jazz Pharmaceuticals make?

Jazz Pharmaceuticals (NASDAQ:JAZZ) has a market capitalization of $8.06 billion and generates $3.66 billion in revenue each year. The specialty pharmaceutical company earns $-224,060,000.00 in net income (profit) each year or ($2.54) on an earnings per share basis.

How many employees does Jazz Pharmaceuticals have?

The company employs 2,800 workers across the globe.

Does Jazz Pharmaceuticals have any subsidiaries?
The following companies are subsidiares of Jazz Pharmaceuticals: Cavion.
Read More
How can I contact Jazz Pharmaceuticals?

Jazz Pharmaceuticals' mailing address is FIFTH FLOOR WATERLOO EXCHANGE WATERLOO ROAD, DUBLIN L2, D04. The official website for the company is www.jazzpharma.com. The specialty pharmaceutical company can be reached via phone at (531) 634-7800, via email at investorinfo@jazzpharma.com, or via fax at 353-1634-7850.

This page (NASDAQ:JAZZ) was last updated on 5/28/2023 by MarketBeat.com Staff

My Account -